Global Minimally Invasive Biopsy Technologies Market

Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Fine Needle Aspiration, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries’ Data - Analysis and Forecast, 2019-2030

Published Year: 2020
SKU: BH00808SA

5000

Online Access for One Person. Permission to Print

A quick peek into the report

Market Overview

The minimally invasive biopsy technologies market industry analysis by BIS Research projects the market to grow at a significant C

Market Overview and Estimation

Cancer is estimated as the leading cause of death worldwide and accounted for an around 9.6 million deaths in 2018, as per WHO. The treatment of cancer is highly dependent on profiling a piece of biopsied tumor tissue. The ease of acquiring the tissue, however, depends greatly on the patient’s condition and tumor accessibility. For example, in advanced or metastatic non-small cell lung cancers (NSCLC), there are over 31% chances of not having an accessible tissue.

Likewise, the cancers associated with late-stage presentation of symptoms are often difficult to diagnose in their asymptomatic phase. Furthermore, since the tumors are characterized by intra-tumor heterogeneity, a tissue biopsy might fail in capturing the newly evolving and genetically distinct cells. Adequate supervision of cancer also involves periodic monitoring to check for progression and recurrence, and since biopsy is painful and expensive, there is a high degree of patient non-compliance toward tissue biopsy.

Moreover, the imaging modalities including ultrasound, positron emission tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI) are incapable of detecting many early stage cancers and even the small metastatic tumors. While these challenges have hampered the process of effective cancer management, the use of minimally invasive biopsy technologies to capture the genomic content in various body fluids such as blood, urine, saliva, sweat, breath, and tears combined with sensitive genotyping assays is becoming increasingly prevalent.

The minimally invasive biopsy technologies market industry analysis by BIS Research highlights the market is expected to witness a growth of significant CAGR of 12.82% during the forecast period, 2019-2030. The market generated a market revenue of $924.8 million in 2018.

The market growth is primarily attributed to the growth drivers including increasing increasing global burden of cancer, growing awareness related to early disease diagnosis, and increasing demand for minimally invasive diagnostics. However, there are significant challenges, restraining the market growth. These challenges include stringent regulatory guidelines, the high cost of technologies, and the lack of adequate reimbursement policies.

Minimally Invasive Biopsy Technologies Industry

 

Growth Drivers

 

• Rising Global Burden of Cancer

• Increasing Number of Cross-Industry Collaborations
• Growing Prominence of Precision Medicine

 

Market Challenges

 

• Uncertain Regulatory Requirements

• Lack of Favorable Reimbursement Policies

• Technical Challenges Associated with the Analysis of Circulating Biomarkers

 

Market Opportunities

 

• Business Expansion in Emerging Economies

• Integration of Artificial Intelligence (AI)

• Rising Number of Initiatives by the Government

Growth Factors

  • Rising Global Burden of Cancer: With the increasing life-span and exposure to risk factors such as smoking, sun exposure, radiation exposure, chemicals, and other substances, the number of new cases of cancer is increasing at alarming rates throughout the globe. The cost of cancer care in countries within the Europe and Asia-Pacific region are increasing at unprecedented rates. Owing to the rising cancer expenditures in different countries, healthcare providers across the world are promoting the use of innovative molecular diagnostics for the early detection as well as effective management of cancer. The products under the global minimally invasive biopsy technologies market hold huge potential for the early detection and proper management of cancer and are thus increasingly being employed to reduce the rising worldwide burden associated with cancer.
  • Increasing Number of Cross-Industry Collaborations: The manufacturers in the market are entering into a significant number of cross-industry partnerships and collaborations for the development of novel minimally invasive tests or for the expansion of their customer base. Some of the leading manufacturers have also executed collaborations with the research institutions which are specializing in precision medicine and oncology. For instance, in April 2018, Biocept, Inc. collaborated with OHSU Knight Cancer Institute to increase the adoption of liquid biopsy testing and to co-develop additional assay platform capabilities with the institute.
  • Growing Prominence of Precision Medicine: Precision medicine is a customized medical model which involves the tailoring of medical treatment, decisions, practices, and interventions to the individual characteristics of each patient. The minimally invasive biopsy technologies such as liquid biopsy hold immense potential for informing various advances in the field of precision medicine. Since liquid biopsy involves the isolation and analysis of cancer biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell free- DNA (cfDNA), and extracellular vesicles (EVs) from the body fluids (blood, cerebrospinal fluid, saliva, and urine), it is capable of providing clinically-actionable information for driving precision medicine.

Key Questions Answered in this Report:

What are the various minimally invasive biopsy technologies available in the market?

•    What are the various minimally invasive biopsy technologies available in the market?
•    What are the major market drivers, challenges, and opportunities in the global minimally invasive biopsy technologies market?
•    What is the current market size and future potential of these technologies?
•    How is the integration of AI expected to impact the market growth during the forecast period?
•    What is the role of minimally invasive biopsy technologies in drug discovery and clinical research?
•    How are minimally invasive biopsy technologies expected to drive precision medicine during the forecast period?
•    How are technologies such as optical biopsy, breath biopsy, and skin assays expected to evolve in the future?
•    What are the guidelines implemented by different government bodies to regulate the approval of minimally invasive biopsy technologies?
•    Which are the established as well as emerging players in this market and what key strategies are being followed by them to establish a strong foothold in the market?
•    Which therapeutic application market is estimated to witness massive incorporation of the minimally invasive biopsy technologies market in the forecast period?
•    Which clinical application is expected to dominate the market during the forecast period?
•    Which technological advancements are expected to impact the market growth in the future?

Report Description

The research report on global minimally invasive biopsy technologies market provides a holistic view of the market in terms of var

Market Report Coverage - Global Minimally Invasive Biopsy Technologies Market

 

 

Base Year

 

2018

 

Market Size by 2018

 

$924.8 million

 

Forecast Period

 

2019-2030

 

Value Estimation by 2030

 

 

 

CAGR During Forecast Period

 

12.82%

 

Number of Tables

 

 

 

Market Segmentation

 

• Liquid Biopsy by Product -  Tests, Kits And Consumables, And Instruments

• Liquid Biopsy by Circulating Biomarker -  Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Cell-Free DNA (cfDNA), and Extracellular Vesicles and Others

• Liquid Biopsy by Clinical Application - Treatment Monitoring, Prognosis and Recurrence Monitoring, Treatment Selection, and Diagnosis and Screening

• Liquid Biopsy by Therapeutic Application - Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Blood Cancer, Other Types of Cancer, and Non-Oncology Applications

 

 

Regional Segmentation

 

• North America – U.S. and Canada

• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

• Latin America and Middle East – Brazil, Mexico, Saudi Arabia, and Rest-of-Latin America and the Middle East

 

Key Companies Profiled

 

The key manufacturers who have been contributing significantly to the global minimally invasive biopsy technologies market include Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc., among others.

Market Segmentation

Market Outlook by Technology

Based on the type of minimally invasive biopsy technology, the global minimally invasive biopsy technologies market has been segmented into liquid biopsy, optical biopsy, and other technologies (brush biopsy, fine needle aspiration, pigmented lesion assays, and breath biopsy). While liquid biopsy has already made its entry in the market since the past few years, optical biopsy and other technologies are expected to evolve by the coming decade.

Minimally Invasive Biopsy Technologies Market

Liquid biopsy is the leading contributor to the global minimally invasive biopsy technologies market. This can primarily be attributed to the worldwide commercial availability of a large number of liquid biopsy tests, kits, and instruments. Moreover, the segment is composed of a significant number of established as well as emerging players, focused at continuous innovation in the field of liquid biopsy owing to which the technology is expected to witness an accelerating growth during the forecast period.

On the other hand, optical biopsy and other technologies account for a lesser share in the market since these technologies are still evolving. Moreover, attributed to the anticipated launch of innovative products, these segments are expected to grow at moderate pace during the forecast period.

By Region

The potential of the global minimally invasive imaging market with respect to different regions, namely, North America, Europe, Asia-Pacific, Latin America and the Middle East, and Rest-of-the-World, has been described in this chapter.

The chapter also comprises regional as well as country-level analysis of the different technologies in the global minimally invasive biopsy technologies market, along with the key growth drivers, restraints and challenges, and opportunities.

Further, the chapter analyzes the ongoing trends in the industry in major regions by probing into the past and the present government regulations and the various macro- and micro-economic factors.

In 2018, the region of North America dominated the entire market with a market share of 60.42% and is expected to dominate in future as well among all other regions. However, Europe is expected to witness the maximum growth during the forecast period.

Table of Contents

1 Product Definition

         1.1    Inclusions and Exclusions

2 Research Scope

          2.1    Scope of Work
          2.2    Key Questions Answered in the Report

3 Research Methodology

         3.1    Global Minimally Invasive Biopsy Technologies Market: Research Methodology
                  3.1.1    Primary Data Sources
                  3.1.2    Secondary Data Sources
                  3.1.3    Selection Criteria for Company Profiles

4 Industry Analysis

         4.1    Industry Ecosystem
         4.2    Regulatory Framework and Government Initiatives
                  4.2.1    Liquid Biopsy: Regulatory Framework
                              4.2.1.1    Liquid Biopsy: Regulations in the U.S.
                              4.2.1.2    Liquid Biopsy: Regulations in Other Countries
                  4.2.2    Optical Biopsy and Other Technologies: Regulatory Framework
                              4.2.2.1    Optical Biopsy and Other Technologies: Regulations in the U.S.
                              4.2.2.2    Optical Biopsy and Other Technologies: Regulations in the Europe
                              4.2.2.3    Optical Biopsy and Other Technologies: Regulations in Other Countries
         4.3    Patent Analysis
                  4.3.1    Liquid Biopsy: Patent Analysis
                  4.3.2    Optical Biopsy: Patent Analysis
         4.4    Physician’s Perception

5 Competitive Landscape

         5.1    Key strategies and Developments
                  5.1.1    Partnerships, Alliances, and Business Expansions
                  5.1.2    New Offerings
                  5.1.3    Funding Activities
                  5.1.4    Procurement and Sales Agreements
                  5.1.5    Regulatory and Legal Developments
                  5.1.6    Mergers and Acquisitions
         5.2    Market Share Analysis
                  5.2.1    Market Share Analysis: Global Liquid Biopsy Market
                  5.2.2    Market Share Analysis: Global Optical Biopsy Market
                  5.2.3    Market Share Analysis: Global Other Technologies Market
         5.3    Growth Share Analysis
                  5.3.1    Growth Share Matrix (by Technology)
                  5.3.2    Growth Share Matrix (by Therapeutic Application)
                  5.3.3    Growth Share Matrix (by Region)

6 Global Minimally Invasive Biopsy Technologies Market, 2018-2030

         6.1    Assumptions and Limitations
         6.2    Key Findings and Opportunity Assessment
         6.3    Global Minimally Invasive Biopsy Technologies, Market Scenario
                  6.3.1    Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)
                  6.3.2    Market Dynamics
                              6.3.2.1    Overview
                              6.3.2.2    Impact Analysis
                              6.3.2.3    Market Drivers
                                             6.3.2.3.1    Rising Global Burden of Cancer
                                             6.3.2.3.2    Increasing Number of Cross-Industry Collaborations
                                             6.3.2.3.3    Growing Prominence of Precision Medicine
                              6.3.2.4    Market Restraints
                                             6.3.2.4.1    Uncertain Regulatory Requirements
                                             6.3.2.4.2    Lack of Favorable Reimbursement Policies
                                             6.3.2.4.3    Technical Challenges Associated with the Analysis of Circulating Biomarkers
                              6.3.2.5    Market Opportunities
                                             6.3.2.5.1    Business Expansion in Emerging Economies
                                             6.3.2.5.2    Integration of Artificial Intelligence (AI)
                                             6.3.2.5.3    Rising Number of Initiatives by the Government
         6.4    Market Estimation Method

7 Global Minimally Invasive Biopsy Technologies Market, by Technology, 2018-2030

         7.1    Overview
         7.2    Global Liquid Biopsy Market Scenario, 2018-2030
                  7.2.1    Principle and Advantages of Liquid Biopsy
                  7.2.2    Key Findings and Opportunity Assessment
                  7.2.3    Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)
                              7.2.3.1    Market Dynamics
                                             7.2.3.1.1    Impact Analysis
                                             7.2.3.1.2    Market Drivers
                                                               7.2.3.1.2.1    Increasing Demand for Liquid Biopsy Tests
                                                               7.2.3.1.2.2    Recent Product Launches and Approvals
                                                               7.2.3.1.2.3    Strong Pipeline
                                             7.2.3.1.3    Market Restraints
                                                               7.2.3.1.3.1    Uncertain Regulatory Requirements
                                                               7.2.3.1.3.2    Lack of Adequate Reimbursement
                  7.2.4    Global Liquid Biopsy Market Segmentation
                              7.2.4.1    Global Liquid Biopsy Market (by Product), 2018-2030
                                             7.2.4.1.1    Overview
                                             7.2.4.1.2    Tests
                                             7.2.4.1.3    Kits and Consumables
                                             7.2.4.1.4    Instruments
                              7.2.4.2    Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)
                                             7.2.4.2.1    Overview
                                             7.2.4.2.2    Circulating Tumor DNA (ctDNA)
                                             7.2.4.2.3    Circulating Tumor Cells (CTCs)
                                             7.2.4.2.4    Cell-Free DNA (cfDNA)
                                             7.2.4.2.5    Extracellular Vesicles and Others
                              7.2.4.3    Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)
                                             7.2.4.3.1    Overview
                                             7.2.4.3.2    Treatment Monitoring
                                             7.2.4.3.3    Prognosis and Recurrence Monitoring
                                             7.2.4.3.4    Treatment Selection
                                             7.2.4.3.5    Diagnosis and Screening
                              7.2.4.4    Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)
                                             7.2.4.4.1    Overview
                                             7.2.4.4.2    Lung Cancer
                                             7.2.4.4.3    Breast Cancer
                                             7.2.4.4.4    Prostate Cancer
                                             7.2.4.4.5    Colorectal Cancer
                                             7.2.4.4.6    Blood Cancer
                                             7.2.4.4.7    Other Types of Cancer
                                             7.2.4.4.8    Non-Oncology Applications
         7.3    Global Optical Biopsy Market Scenario, 2018-2030
                  7.3.1    Principle and Advantages of Optical Biopsy
                  7.3.2    Key Findings and Opportunity Assessment
                  7.3.3    Global Optical Biopsy Market, Market Size and Forecast (2018-2030)
                              7.3.3.1    Market Dynamics
                                             7.3.3.1.1    Impact Analysis
                                             7.3.3.1.2    Market Drivers
                                                               7.3.3.1.2.1    Recent Product Launches and Approvals
                                                               7.3.3.1.2.2    Significant Number of Funding and Investments
                                                               7.3.3.1.2.3    Anticipated Product Launches
                                             7.3.3.1.3    Market Restraints
                                                               7.3.3.1.3.1    Lack of Favorable Reimbursement
                                                               7.3.3.1.3.2    Stringent Regulatory Guidelines
                  7.3.4    Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
                              7.3.4.1    Overview
                              7.3.4.2    Oncology
                              7.3.4.3    Non-Oncology Applications
         7.4    Global Other Technologies Market Scenario, 2018-2030
                  7.4.1    Overview
                  7.4.2    Key Findings and Opportunity Assessment
                  7.4.3    Global Other Technologies Market, Market Size and Forecast (2018-2030)
                              7.4.3.1    Market Dynamics
                                             7.4.3.1.1    Impact Analysis
                                             7.4.3.1.2    Market Drivers
                                                               7.4.3.1.2.1    Ongoing Strategic Collaborations and M&A Activities
                                                               7.4.3.1.2.2    Strong Product Pipeline
                                             7.4.3.1.3    Market Restraints
                                                               7.4.3.1.3.1    Poor Reimbursement Scenario
                                                               7.4.3.1.3.2    Limited Scope of Expansion in Emerging Economies
                  7.4.4    Global Other Technologies Market, (by Therapeutic Application)
                              7.4.4.1    Overview
                              7.4.4.2    Lung Cancer
                              7.4.4.3    Melanoma
                              7.4.4.4    Thyroid Cancer
                              7.4.4.5    Non-Oncology Applications

8 Global Minimally Invasive Biopsy Technologies Market, (by Region), 2018-2030

         8.1    Overview and Key Findings
         8.2    North America
                  8.2.1    Market Footprint: North America Minimally Invasive Biopsy Technologies Market
                              8.2.1.1    Market Dynamics
                                             8.2.1.1.1    Impact Analysis
                  8.2.2    North America: Liquid Biopsy Market
                              8.2.2.1    North America: Liquid Biopsy Market, By Country
                                             8.2.2.1.1    U.S.
                                             8.2.2.1.2    Canada
                  8.2.3    North America: Optical Biopsy Market
                              8.2.3.1    North America: Optical Biopsy Market, by Country
                                             8.2.3.1.1    U.S.
                                             8.2.3.1.2    Canada
                  8.2.4    North America: Other Technologies Market
                              8.2.4.1    North America: Other Technologies Market, By Country
                                             8.2.4.1.1    U.S.
                                             8.2.4.1.2    Canada
         8.3    Europe
                  8.3.1    Market Footprint: Europe Minimally Invasive Biopsy Technologies Market
                              8.3.1.1    Market Dynamics
                                             8.3.1.1.1    Impact Analysis
                  8.3.2    Europe: Liquid Biopsy Market
                              8.3.2.1    Europe: Liquid Biopsy Market, By Country
                                             8.3.2.1.1    Germany
                                             8.3.2.1.2    France
                                             8.3.2.1.3    U.K.
                                             8.3.2.1.4    Italy
                                             8.3.2.1.5    Spain
                                             8.3.2.1.6    Rest-of-Europe
                  8.3.3    Europe: Optical Biopsy Market
                              8.3.3.1    Europe: Optical Biopsy Market, by Country
                                             8.3.3.1.1    Germany
                                             8.3.3.1.2    U.K.
                                             8.3.3.1.3    France
                                             8.3.3.1.4    Netherlands
                                             8.3.3.1.5    Rest-of-Europe
                  8.3.4    Europe: Other Technologies Market
                              8.3.4.1    Europe: Other Technologies Market, By Country
                                             8.3.4.1.1    U.K.
                                             8.3.4.1.2    Germany
                                             8.3.4.1.3    Switzerland
         8.4    Asia-Pacific
                  8.4.1    Market Footprint: Asia-Pacific Minimally Invasive Biopsy Technologies Market
                              8.4.1.1    Market Dynamics
                                             8.4.1.1.1    Impact Analysis
                  8.4.2    Asia-Pacific: Liquid Biopsy Market
                              8.4.2.1    Asia-Pacific: Liquid Biopsy Market, by Country
                                             8.4.2.1.1    China
                                             8.4.2.1.2    Japan
                                             8.4.2.1.3    India
                                             8.4.2.1.4    Australia
                                             8.4.2.1.5    South Korea
                                             8.4.2.1.6    Singapore
                                             8.4.2.1.7    Rest-of-Asia-Pacific
                  8.4.3    Asia-Pacific: Optical Biopsy Market
                              8.4.3.1    Asia-Pacific: Optical Biopsy Market, by Country
                                             8.4.3.1.1    Japan
                                             8.4.3.1.2    China
                                             8.4.3.1.3    South Korea
                                             8.4.3.1.4    Rest-of Asia-Pacific
         8.5    Latin America and the Middle East
                  8.5.1    Market Footprint: Latin America and the Middle East Minimally Invasive Biopsy Technologies Market
                              8.5.1.1    Market Dynamics
                                             8.5.1.1.1    Impact Analysis
                  8.5.2    Latin America and the Middle East: Liquid Biopsy Market
                              8.5.2.1    Latin America and the Middle East: Liquid Biopsy Market, By Country
                                             8.5.2.1.1    Brazil
                                             8.5.2.1.2    Mexico
                                             8.5.2.1.3    Saudi Arabia
                                             8.5.2.1.4    Rest-of-Latin America and the Middle East
                  8.5.3    Latin America and the Middle East: Optical Biopsy Market
         8.6    Rest-of-the-World
                  8.6.1    Market Footprint: Rest-of-the-World Minimally Invasive Biopsy Technologies Market
                              8.6.1.1    Market Dynamics
                                             8.6.1.1.1    Impact Analysis
                  8.6.2    Rest-of-the-World: Liquid Biopsy Market
                  8.6.3    Rest-of-the-World: Optical Biopsy Market

9 Company Profiles

         9.1    Abcodia Ltd.
                  9.1.1    Company Overview
                  9.1.1 Role of Abcodia Ltd. in the Global Minimally Invasive Biopsy Technologies Market
                  9.1.2 SWOT Analysis: Abcodia Ltd.
         9.2    Adaptive Biotechnologies
                  9.2.1    Company Overview
                  9.2.2    Role of Adaptive Biotechnologies in the Global Minimally Invasive Biopsy Technologies Market
                  9.2.3    Financials
                  9.2.4    SWOT Analysis: Adaptive Biotechnologies
         9.3    Biocept, Inc.
                  9.3.1    Company Overview
                  9.3.2    Role of Biocept, Inc. in the Global Minimally Invasive Biopsy Technologies Market
                  9.3.3    Financials
                              9.3.3.1    Key Insights on the Financial Health of the Company
                  9.3.4    SWOT Analysis: Biocept, Inc.
         9.4    Caliber Imaging & Diagnostics
                  9.4.1    Company Overview
                  9.4.2    Role of Caliber Imaging & Diagnostics in the Global Minimally Invasive Biopsy Technologies Market
                  9.4.3    SWOT Analysis: Caliber Imaging & Diagnostics
         9.5    Chronix Biomedical
                  9.5.1    Company Overview
                  9.5.2    Role of Chronix Biomedical in the Global Minimally Invasive Biopsy Technologies Market
                  9.5.3    SWOT Analysis: Chronix Biomedical
         9.6    DermTech
                  9.6.1    Company Overview
                  9.6.2    Role of DermTech in the Global Minimally Invasive Biopsy Technologies Market
                  9.6.3    Financials
                              9.6.3.1    Key Insights on the Financial Health of the Company
                  9.6.4    SWOT Analysis: DermTech
         9.7    F. Hoffmann-La Roche Ltd
                  9.7.1    Company Overview
                  9.7.2    Role of F. Hoffmann-La Roche Ltd in the Global Minimally Invasive Biopsy Technologies Market
                  9.7.3    Financials
                              9.7.3.1 Key Insights on the Financial Health of the Company
                  9.7.4    SWOT Analysis: F. Hoffmann-La Roche Ltd
         9.8    Guardant Health, Inc.
                  9.8.1    Company Overview
                  9.8.2    Role of Guardant Health, Inc. in the Global Minimally Invasive Biopsy Technologies Market
                  9.8.3    Financials
                              9.8.3.1    Key Insights on the Financial Health of the Company
                  9.8.4    SWOT Analysis: Guardant Health, Inc.
         9.9    Mauna Kea Technologies
                  9.9.1    Company Overview
                  9.9.2    Role of Mauna Kea Technologies in the Global Minimally Invasive Biopsy Technologies Market
                  9.9.3    Financials
                              9.9.3.1    Key Insights on the Financial Health of the Company
                  9.9.4    SWOT Analysis: Mauna Kea Technologies
        9.10   Myriad Genetics
                  9.10.1    Company Overview
                  9.10.2    Role of Myriad Genetics in the Global Minimally Invasive Biopsy Technologies Market
                  9.10.3    Financials
                                9.10.3.1    Key Insights on the Financial Health of the Company
                  9.10.4    SWOT Analysis: Myriad Genetics
        9.11   NeoGenomics Laboratories, Inc.
                  9.11.1    Company Overview
                  9.11.2    Role of NeoGenomics Laboratories, Inc. in the Global Minimally Invasive Biopsy Technologies Market
                  9.11.3    Financials
                                9.11.3.1    Key Insights on the Financial Health of the Company
                  9.11.4    SWOT Analysis: NeoGenomics Laboratories, Inc.
        9.12   Owlstone Medical Ltd
                  9.12.1    Company Overview
                  9.12.2    Role of Owlstone Medical Ltd in the Global Minimally Invasive Biopsy Technologies Market
                  9.12.3    SWOT Analysis: Owlstone Medical Ltd
        9.13   QIAGEN
                  9.13.1    Company Overview
                  9.13.2    Role of QIAGEN in the Global Minimally Invasive Biopsy Technologies Market
                  9.13.3    Financials
                                9.13.3.1    Key Insights on the Financial Health of the Company
                  9.13.4    SWOT Analysis: QIAGEN
        9.14   Thermo Fisher Scientific
                  9.14.1    Company Overview
                  9.14.2    Role of Thermo Fisher Scientific in the Global Minimally Invasive Biopsy Technologies Market
                  9.14.3    Financials
                                9.14.3.1    Key Insights on the Financial Health of the Company
                  9.14.4    SWOT Analysis: Thermo Fisher Scientific
        9.15   Veracyte, Inc.
                  9.15.1    Company Overview
                  9.15.2    Role of Veracyte, Inc. in the Global Minimally Invasive Biopsy Technologies Market
                  9.15.3    Financials
                                9.15.3.1    Key Insights on the Financial Health of the Company
                  9.15.4    SWOT Analysis: Veracyte, Inc.

List of Tables

Table 4.1:    Guidance Documents for the FDA Approval of Liquid Biopsies
Table 4.2:    Regulatory Bodies in Other Countries
Table 6.1:    Market Drivers
Table 6.2:    Market Restraints
Table 6.3:    Global Cancer Statistics (by Region), 2018
Table 6.4:    National Expenditures for Cancer Care in the U.S. ($Billion)
Table 6.5:    5-Year Prevalence (2018) of Major Cancer Types
Table 7.1:    Market Drivers
Table 7.2:    Market Restraints
Table 7.3:    Liquid Biopsy: Recent Launches and Approvals
Table 7.4:    Liquid Biopsy: Pipeline
Table 7.5:    Market Drivers
Table 7.6:    Market Restraints
Table 7.7:    Optical Biopsy: Recent Launches and Approvals
Table 7.8:    Market Drivers
Table 7.9:    Market Restraints
Table 7.10:    Pipeline Products
Table 8.1:    Market Drivers
Table 8.2:    Market Restraints
Table 8.3:    Market Drivers
Table 8.4:    Market Restraints
Table 8.6:    Market Drivers
Table 8.7:    Market Restraints
Table 8.8:    Market Drivers
Table 8.9:    Market Restraints
Table 8.10:    Market Drivers
Table 8.11:    Market Restraints

List of Figures

Figure 1:    Global Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 2:    Impact Analysis of Market Drivers and Market Restraints, 2018-2030
Figure 3:    Leading Players in the Global Minimally Invasive Biopsy Technologies Market
Figure 4:    Share of Key Developments and Strategies, January 2015-December 2019
Figure 2.1:    Global Minimally Invasive Biopsy Technologies Market Segmentation
Figure 3.1:    Research Methodology
Figure 3.2:    Primary Research
Figure 3.3:    Secondary Research
Figure 3.4:    Data Triangulation
Figure 3.5:    Bottom-up Approach (Segment-Wise Analysis)
Figure 3.6:    Top-Down Approach (Segment-Wise Analysis)
Figure 3.7:    Assumptions and Limitations
Figure 3.8:    Considered Factors for Data Prediction and Modelling
Figure 3.9:    Shares of Key Company Profiles
Figure 4.1:    Industry Ecosystem
Figure 4.2:    Evolution of FDA Guidelines for the Approval of Companion Diagnostics
Figure 4.3:    Number of Patents in Liquid Biopsy (2011-2019)
Figure 4.4:    Number of Patents in Optical Biopsy (2011-2019)
Figure 5.1:    Share of Key Developments and Strategies, January 2015-December 2019
Figure 5.2:    Share of Partnerships, Alliances and Business Expansions, January 2015-December 2019
Figure 5.3:    Share of New Offerings, January 2015-December 2019
Figure 5.4:    Share of Funding Activities, January 2015-December 2019
Figure 5.5:    Share of Procurement and Sales Agreements, January 2015-December 2019
Figure 5.6:    Share of Regulatory and Legal Developments, January 2015-December 2019
Figure 5.7:    Share of Mergers and Acquisitions, January 2015-December 2019
Figure 5.8:    Market Share Analysis: Global Liquid Biopsy Market, 2018
Figure 5.9:    Market Share Analysis: Global Liquid Biopsy Market, 2017
Figure 5.10:    Market Share Analysis: Global Optical Biopsy Market, 2018
Figure 5.11:    Market Share Analysis: Global Optical Biopsy Market, 2018
Figure 5.12:    Market Share Analysis: Global Other Technologies Market, 2018
Figure 5.13:    Market Share Analysis: Global Other Technologies Market, 2017
Figure 5.14:    Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
Figure 5.15:    Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Therapeutic Application), 2018-2030
Figure 5.16:    Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Region), 2018-2030
Figure 6.1:    Global Minimally Invasive Biopsy Technologies Market, 2030 Opportunity Assessment
Figure 6.2:    Global Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 7.1:    Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
Figure 7.2:    Global Liquid Biopsy Market, 2030 Opportunity Assessment
Figure 7.3:    Global Liquid Biopsy Market, 2018-2030
Figure 7.4:    Global Liquid Biopsy Market Segmentation
Figure 7.5:    Global Liquid Biopsy Market (by Product), 2018-2030
Figure 7.6:    Global Liquid Biopsy Market (by Tests), 2018-2030
Figure 7.7:    Global Liquid Biopsy Market (by Kits and Consumables), 2018-2030
Figure 7.8:    Global Liquid Biopsy Market (by Instruments), 2018-2030
Figure 7.9:    Global Liquid Biopsy Market (by Circulating Biomarkers), 2018-2030
Figure 7.10:    Global Liquid Biopsy Market (by ctDNA), 2018-2030
Figure 7.11:    Global Liquid Biopsy Market (by CTCs), 2018-2030
Figure 7.12:    Global Liquid Biopsy Market (by cfDNA), 2018-2030
Figure 7.13:    Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2018-2030
Figure 7.14:    Global Liquid Biopsy Market (by Clinical Application), 2018-2030
Figure 7.15:    Global Liquid Biopsy Market (by Treatment Monitoring), 2018-2030
Figure 7.16:    Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2018-2030
Figure 7.17:    Global Liquid Biopsy Market (by Treatment Selection), 2018-2030
Figure 7.18:    Global Liquid Biopsy Market (by Diagnosis and Screening), 2018-2030
Figure 7.19:    Global Liquid Biopsy Market (by Therapeutic Application), 2018-2030
Figure 7.20:    Global Liquid Biopsy Market (by Lung Cancer), 2018-2030
Figure 7.21:    Global Liquid Biopsy Market (by Breast Cancer), 2018-2030
Figure 7.22:    Global Liquid Biopsy Market (by Prostate Cancer), 2018-2030
Figure 7.23:    Global Liquid Biopsy Market (by Colorectal Cancer), 2018-2030
Figure 7.24:    Global Liquid Biopsy Market (by Blood Cancer), 2018-2030
Figure 7.25:    Global Liquid Biopsy Market (by Other Types of Cancer), 2018-2030
Figure 7.26:    Global Liquid Biopsy Market (by Non-Oncology Applications),  2018-2030
Figure 7.27:    Global Optical Biopsy Market, 2030 Opportunity Assessment
Figure 7.28:    Global Optical Biopsy Market, 2018-2030
Figure 7.29:    Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
Figure 7.30:    Global Optical Biopsy Market (by Oncology), 2018-2030
Figure 7.31:    Global Optical Biopsy Market (by Oncology), 2018-2030
Figure 7.32:    Other Technologies
Figure 7.33:    Global Other Technologies Market, 2030 Opportunity Assessment
Figure 7.34:    Global Other Technologies Market, 2018-2030
Figure 7.35:    Global Other Technologies Market (by Therapeutic Application),  2018-2030
Figure 7.36:    Global Other Technologies Market (by Lung Cancer), 2018-2030
Figure 7.37:    Global Other Technologies Market (by Melanoma), 2018-2030
Figure 7.38:    Global Other Technologies Market (by Thyroid Cancer), 2018-2030
Figure 7.39:    Global Other Technologies Market (by Non-Oncology Applications), 2018-2030
Figure 8.1:    Global Minimally Invasive Biopsy Technologies Market Scenario,  2018 and 2030
Figure 8.2:    North America: Minimally Invasive Biopsy Technologies Market,  2018-2030
Figure 8.3:    North America: Liquid Biopsy Market, 2018-2030
Figure 8.4:    North America: Liquid Biopsy Market Dynamics
Figure 8.5:    North America: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.6:    U.S.: Liquid Biopsy Market, 2018-2030
Figure 8.7:    Canada: Liquid Biopsy Market, 2018-2030
Figure 8.8:    North America: Optical Biopsy Market, 2018-2030
Figure 8.9:    North America: Optical Biopsy Market Dynamics
Figure 8.10:    North America: Optical Biopsy Market (by Country), 2018-2030
Figure 8.11:    U.S.: Optical Biopsy Market, 2018-2030
Figure 8.12:    Canada: Optical Biopsy Market, 2018-2030
Figure 8.13:    North America: Other Technologies Market, 2018-2030
Figure 8.14:    North America: Other Technologies Market Dynamics
Figure 8.15:    North America: Other Technologies Market (by Country), 2018-2030
Figure 8.16:    U.S.: Other Technologies Market, 2018-2030
Figure 8.17:    Canada: Other Technologies Market, 2018-2030
Figure 8.18:    Europe: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.19:    Europe: Liquid Biopsy Market, 2018-2030
Figure 8.20:    Europe: Liquid Biopsy Market Dynamics
Figure 8.21:    Europe: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.22:    Germany: Liquid Biopsy Market, 2018-2030
Figure 8.23:    France: Liquid Biopsy Market, 2018-2030
Figure 8.24:    U.K.: Liquid Biopsy Market, 2018-2030
Figure 8.25:    Italy: Liquid Biopsy Market, 2018-2030
Figure 8.26:    Spain: Liquid Biopsy Market, 2018-2030
Figure 8.27:    Rest-of-Europe: Liquid Biopsy Market, 2018-2030
Figure 8.28:    Europe: Optical Biopsy Market, 2018-2030
Figure 8.29:    Europe: Optical Biopsy Market Dynamics
Figure 8.30:    Europe: Optical Biopsy Market (by Country), 2018-2030
Figure 8.31:    Germany: Optical Biopsy Market, 2018-2030
Figure 8.32:    U.K.: Optical Biopsy Market, 2018-2030
Figure 8.33:    France: Optical Biopsy Market, 2018-2030
Figure 8.34:    Netherlands: Optical Biopsy Market, 2018-2030
Figure 8.35:    Rest-of-Europe: Optical Biopsy Market, 2018-2030
Figure 8.36:    Europe: Other Technologies Market, 2018-2030
Figure 8.37:    Europe: Other Technologies Market Dynamics
Figure 8.38:    Europe: Other Technologies Market (by Country), 2018-2030
Figure 8.39:    U.K: Other Technologies Market, 2018-2030
Figure 8.40:    Germany: Other Technologies Market, 2018-2030
Figure 8.41:    Switzerland: Other Technologies Market, 2018-2030
Figure 8.42:    Asia-Pacific: Minimally Invasive Biopsy Technologies Market,  2018-2030
Figure 8.43:    Asia-Pacific: Liquid Biopsy Market, 2018-2030
Figure 8.44:    Asia-Pacific: Liquid Biopsy Market Dynamics
Figure 8.45:    Asia-Pacific: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.46:    China: Liquid Biopsy Market, 2018-2030
Figure 8.47:    Japan: Liquid Biopsy Market, 2018-2030
Figure 8.48:    India: Liquid Biopsy Market, 2018-2030
Figure 8.49:    Australia: Liquid Biopsy Market, 2018-2030
Figure 8.50:    South Korea: Liquid Biopsy Market, 2018-2030
Figure 8.51:    Singapore: Liquid Biopsy Market, 2018-2030
Figure 8.52:    Rest-of-Asia-Pacific: Liquid Biopsy Market, 2018-2030
Figure 8.53:    Asia-Pacific: Optical Biopsy Market, 2018-2030
Figure 8.54:    Asia-Pacific: Optical Biopsy Market Dynamics
Figure 8.55:    Asia-Pacific: Optical Biopsy Market (by Country), 2018-2030
Figure 8.56:    Japan: Optical Biopsy Market, 2018-2030
Figure 8.57:    China: Optical Biopsy Market, 2018-2030
Figure 8.58:    South Korea: Optical Biopsy Market, 2018-2030
Figure 8.59:    Rest-of-Asia-Pacific: Optical Biopsy Market, 2018-2030
Figure 8.60:    Latin America and the Middle East: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.61:    Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
Figure 8.62:    Latin America and the Middle East: Liquid Biopsy Market Dynamics
Figure 8.63:    Latin America and the Middle East: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.64:    Brazil: Liquid Biopsy Market, 2018-2030
Figure 8.65:    Mexico: Liquid Biopsy Market, 2018-2030
Figure 8.66:    Saudi Arabia: Liquid Biopsy Market, 2018-2030
Figure 8.67:    Rest-of-Latin America and the Middle East: Liquid Biopsy Market,  2018-2030
Figure 8.68:    Latin America and the Middle East: Optical Biopsy Market, 2018-2030
Figure 8.69:    Rest-of-the-World: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.70:    Rest-of-the-World: Liquid Biopsy Market, 2018-2030
Figure 8.71:    Rest-of-the-World: Optical Biopsy Market, 2018-2030
Figure 9.1:    Abcodia Ltd.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.2:    Adaptive Biotechnologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.3:    Adaptive Biotechnologies Net Revenue (by Business Segment),  2017 and 2018
Figure 9.4:    Biocept, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.5:    Biocept, Inc.: Overall Financials, 2016-2018
Figure 9.6:    Biocept, Inc.: R&D Expense, 2016-2018
Figure 9.7:    Caliber Imaging & Diagnostics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.8:    Chronix Biomedical: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.9:    DermTech: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.10:    DermTech: Financials (Nine Months Ended September 2018-2019
Figure 9.11:    DermTech: R&D Expense, 2016-2018
Figure 9.12:    F. Hoffmann-La Roche Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.13:    F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 9.14:    F. Hoffmann-La Roche Ltd Net Revenue (by Business Segment),  2016-2018
Figure 9.15:    F. Hoffmann-La Roche Ltd: Net Revenue (by Region), 2016-2018
Figure 9.16:    F. Hoffmann-La Roche Ltd: R&D Expense, 2016-2018
Figure 9.17:    Guardant Health, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.18:    Guardant Health, Inc.: Overall Financials, 2016-2018
Figure 9.19:    Guardant Health, Inc.: Net Revenue (by Segment), 2016-2018
Figure 9.20:    Guardant Health, Inc.: Net Revenue (by Region), 2016-2018
Figure 9.21:    Guardant Health, Inc.: R&D Expense, 2016-2018
Figure 9.22:    Mauna Kea Technologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.23:    Mauna Kea Technologies: Overall Financials, 2016-2018
Figure 9.24:    Mauna Kea Technologies Net Revenue (by Activity), 2016-2018
Figure 9.25:    Mauna Kea Technologies: Net Revenue (by Region), 2016-2018
Figure 9.26:    Mauna Kea Technologies: R&D Expense, 2016-2018
Figure 9.27:    Myriad Genetics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.28:    Myriad Genetics: Overall Financials, 2016-2018
Figure 9.29:    Myriad Genetics Net Revenue (by Business Segment), 2016-2018
Figure 9.30:    Myriad Genetics: R&D Expense, 2016-2018
Figure 9.31:    NeoGenomics Laboratories, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.32:    NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 9.33:    NeoGenomics Laboratories, Inc. Net Revenue (by Business Segment), 2016-2018
Figure 9.34:    NeoGenomics Laboratories, Inc.: R&D Expense, 2016-2018
Figure 9.35:    Owlstone Medical Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.36:    QIAGEN: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.37:    QIAGEN: Overall Financials, 2016-2018
Figure 9.38:    QIAGEN Net Revenue (by Product Category), 2016-2018
Figure 9.39:    QIAGEN Net Revenue (by Customer Class), 2016-2018
Figure 9.40:    QIAGEN Net Revenue (by Region), 2016-2018
Figure 9.41:    QIAGEN: R&D Expense, 2016-2018
Figure 9.42:    Thermo Fisher Scientific: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.43:    Thermo Fisher Scientific: Overall Financials, 2016-2018
Figure 9.44:    Thermo Fisher Scientific Net Revenue (by Business Segment),  2016-2018
Figure 9.45:    Thermo Fisher Scientific: Net Revenue (by Region), 2016-2018
Figure 9.46:    Thermo Fisher Scientific: R&D Expense, 2016-2018
Figure 9.47:    Veracyte, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.48:    Veracyte, Inc.: Overall Financials, 2016-2018
Figure 9.49:    Veracyte, Inc.: R&D Expense, 2016-2018

You may also like

Published Year: 2018

Global Liquid Biopsy Market: Focus on Products and Services, Therapeutic Applications, Clinical Applications, Circulating Biomarkers, Country Analysis (16 Countries), Industry Insights, and Competitive Landscape - Analysis and Forecast, 2018-2028

The global liquid biopsy market is anticipated to reach $2.94 billion by 2028, witnessing a...

 
Published Year: 2017

Global Liquid Biopsy Market - Analysis and Forecast, 2017-2025: (Focus on Product Type, Therapeutic Application, End User, Market Share Analysis, Country Analysis, and Competitive Landscape)

The global liquid biopsy market is anticipated to grow over $4,434 million by 2025. With the...

 

Global Minimally Invasive Biopsy Technologies Market

Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Fine Needle Aspiration, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries’ Data - Analysis and Forecast, 2019-2030